Zynerba Pharma CS (ZYNE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2020 | 09-2020 | 06-2020 | 03-2020 | 12-2019 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 59,157 | 64,311 | 77,006 | 60,639 | 70,063 |
| Receivables | 9,043 | 6,533 | 6,529 | 12,907 | 14,614 |
| TOTAL | $73,366 | $74,757 | $85,339 | $75,021 | $87,056 |
| Non-Current Assets | |||||
| PPE Net | 585 | 597 | 641 | 587 | 363 |
| Other Non-Current Assets | 105 | 1,852 | 1,502 | 859 | 346 |
| TOTAL | $691 | $2,448 | $2,143 | $1,446 | $709 |
| Total Assets | $74,057 | $77,205 | $87,482 | $76,466 | $87,765 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 2,523 | 3,404 | 3,883 | 3,328 | 4,741 |
| Accrued Expenses | 11,281 | 6,988 | 8,937 | 6,677 | 7,074 |
| TOTAL | $13,913 | $10,566 | $13,057 | $10,258 | $12,058 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 0 | 0 | 0 | 44 | 110 |
| TOTAL | $N/A | $N/A | $N/A | $44 | $110 |
| Total Liabilities | $13,913 | $10,566 | $13,057 | $10,302 | $12,168 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 41,252 | 29,439 | 29,255 | 24,951 | 23,556 |
| Common Shares | 30 | 29 | 29 | 24 | 23 |
| Retained earnings | -202,173 | -192,555 | -183,506 | -163,173 | -150,836 |
| TOTAL | $60,144 | $66,640 | $74,426 | $66,164 | $75,597 |
| Total Liabilities And Equity | $74,057 | $77,206 | $87,482 | $76,466 | $87,765 |